Development, characterization and in vitro assessement of stearylamine-based lipid nanoparticles of paclitaxel

Pharmazie

Volumn 66, Issue 3, 2011, Pages 171-177

  Pandita, Deepti ^a,b   Ahuja, A ^a   Lather, V ^b   Dutta, T ^c   Velpandian, T ^d   Khar, R K ^a  

^a HAMDARD UNIVERSITY   (India)

^b UNIVERSITY OF MADEIRA   (Portugal)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EXCIPIENT; OCTADECYLAMINE; PACLITAXEL; PHOSPHATIDYLCHOLINE; POLOXAMER; SOLID LIPID NANOPARTICLE; SURFACTANT; AMINE; ANTINEOPLASTIC AGENT; LIPID; NANOPARTICLE; SOLVENT;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MODIFIED SOLVENT INJECTION METHOD; PARTICLE SIZE; REPRODUCIBILITY; STOMACH JUICE; ZETA POTENTIAL; CHEMISTRY; ELECTROCHEMISTRY; FREEZE DRYING; SURFACE PROPERTY; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE; X RAY DIFFRACTION;

AMINES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; ELECTROCHEMISTRY; FREEZE DRYING; GASTRIC JUICE; HUMANS; LECITHINS; LIPIDS; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; POLOXAMER; SOLVENTS; SURFACE PROPERTIES; SURFACE-ACTIVE AGENTS; X-RAY DIFFRACTION;

EID: 79957440923     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2011.0274     Document Type: Article

References (33)

1. Cavalli R (1998) The effect of the components of microemulsions on both size and crystalline structure of solid lipid nanoparticles (SLN) containing a number of model molecules. Pharmazie 53: 392-396.
2. Cavalli R, Caputo O, Gasco MR (2000) Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur J Pharm Sci 10: 305-309. (Pubitemid 30317466)
3. Chang AY, Rubins J, Asbury R, Boros L, Hui LF (2001) Weekly paclitaxel in advanced non-small cell lung cancer. Semin Oncol 28(4 Suppl 14): 10-13. (Pubitemid 32953986)
4. Crosasso P, Ceruti M, Brusa P, Arpicco S, Dosio F, Cattel L (2000) Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J Control Release 63: 19-30. (Pubitemid 30046939)
5. Dong Y, Feng SS (2004) Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 25: 2843-2849. (Pubitemid 38201309)
6. Fonseca C, Simoes S, Gaspar R (2002) Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 83: 273-286. (Pubitemid 35282471)
7. Gasco MR (2007) Lipid nanoparticles: perspectives and challenges. Adv Drug Deliv Rev 59: 377-378.
8. Heiati H, Phillips NC, Tawashi R (1996) Evidence for phospholipid bilayer formation in solid lipid nanoparticles formulated with phospholipid and triglyceride. Pharm Res 13: 1406-1410. (Pubitemid 26344990)
9. Ishitobi M, Shin E, Kikkawa N (2001) Metastatic breast cancer with resistance to both anthracycline and docetaxel successfully treated with weekly paclitaxel. Int J Clin Oncol 6: 55-58. (Pubitemid 32230365)
10. Kan P, Chen ZB, Lee CJ, Chu IM (1999) Development of nonionic surfactant/ phospholipid o/w emulsion as a paclitaxel delivery system. J Control Release 58: 271-278. (Pubitemid 29142451)
11. Kim SY, Lee YM, Baik DJ, Kang JS (2003) Toxic characteristics of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) nanospheres; in vitro and in vivo studies in the normal mice. Biomaterials 24: 55-63. (Pubitemid 35300203)
12. Lee MK, Lim SJ, Kim CK (2007) Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 28: 2137-2146.
13. Lundberg BB (1997) A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). J Pharm Pharmacol 49: 16-21.
14. Mitra A, Lin S (2003) Effect of surfactant on fabrication and characterization of paclitaxel-loaded polybutylcyanoacrylate nanoparticulate delivery systems. J Pharm Pharmacol 55: 895-902. (Pubitemid 36916679)
15. Mu L, Feng SS (2002) Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol). J Control Release 80: 129-144. (Pubitemid 34273754)
16. Muhlen A (1996) Feste Lipid-Nanopartikel mit prolongierter Wirkstof- fliberation: Herstellung, Langzeitstabilität, Charaktersierung, Freisetzungsverhalten and Mechanismen. PhD Thesis, Free University of Berlin, Germany.
17. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95: 351-358. (Pubitemid 9194347)
18. Pandita D, Ahuja A, Velpandian T, Lather V, Dutta T, Khar RK (2009) Characterization and in vitro assessment of paclitaxel loaded lipid nanoparticles formulated using modified solvent injection technique. Pharmazie 64:301-310.
19. Pendri A, Conover CD, Greenwald RB (1998) Antitumor activity of paclitaxel-2′-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug. Anticancer Drug Des 13: 387-395. (Pubitemid 28334027)
20. Potineni A, Lynn DM, Langer R, Amiji MM (2003) Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive biodegradable system for paclitaxel delivery. J Control Release 86: 223-234. (Pubitemid 36084272)
21. Radomska-Soukharev A (2007) Stability of lipid excipients in solid lipid nanoparticles. Adv Drug Deliv Rev 59: 411-418.
22. Rodrigues ML, Carter P, Wirth C, Mullins S, Lee A, Blackburn BK (1995) Synthesis and beta-lactamase-mediated activation of a cephalosporin-taxol prodrug. Chem Biol 2: 223-227.
23. Safavy A, Bonner JA,Waksal HW, Buchsbaum DJ, Gillespie GY, Khazaeli MB, Arani R, Chen DT, Carpenter M, Raisch KP (2003) Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjug Chem 14: 302-310. (Pubitemid 36348653)
24. Schubert MA, Müller-Goymann CC (2003) Solvent injection as a new approach for manufacturing lipid nanoparticles - -evaluation of the method and process parameters. Eur J Pharm Biopharm 55: 125-131. (Pubitemid 36120504)
25. Sharma A, Straubinger RM (1994) Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm Res 11: 889-896. (Pubitemid 24210627)
26. Siekmann B, Westesen K (1994) Melt-homogenized solid lipid nanoparticles stabilized by the nonionic surfactant tyloxapol. Preparation and particle size determination. Pharm Pharmacol Lett 3: 194-197.
27. Souto EB, Muller RH (2006) Applications of lipid nanoparticles (SLN and NLC) in food industry. J Food Technology 4: 90-94.
28. Spencer CM, Faulds D (1994) Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 48: 794-847.
29. Suh H, Jeong B, Rathi R, Kim SW (1998) Regulation of smooth muscle cell proliferation using paclitaxel-loaded poly(ethylene oxide)-poly(lactide/ glycolide) nanospheres. J Biomed Mater Res 42: 331-338. (Pubitemid 28446976)
30. Thigpen JT (2000) Chemotherapy for advanced ovarian cancer: overview of randomized trials. Semin Oncol 27(3 Suppl 7): 11-16.
31. Venkateswarlu V, Manjunath K (2004) Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 95: 627-638.
32. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY (2007) Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 59: 491-504. (Pubitemid 47259227)
33. Wu G, Majewski J, Ege C, Kjaer K,Weygand MJ, Lee KY (2005) Interaction between lipid monolayers and poloxamer 188: an X-ray reflectivity and diffraction study. Biophys J 89: 3159-3173. (Pubitemid 41636071)